Press Releases

Date Title and Summary Additional Formats
Toggle Summary First U.S. Patent Issued for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform
Expands Biocept's intellectual property portfolio to 21 issued patents for its highly sensitive methods of detecting cancer biomarkers on circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA)
View HTML
Toggle Summary Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy
Clinical validation of Biocept's novel PD-L1 test using multiple antibody clones has potential to improve detection, treatment selection, and patient monitoring with cancer immunotherapy
View HTML
Toggle Summary Biocept Reports Third Quarter 2017 Financial Results
-- Despite the impact from natural disasters and fewer sales days, revenues were up 6% and 111% in 3Q 2017 and year to date, respectively, versus the prior-year periods inclusive of the impact of conversion to accrual-based revenue recognition-- Distribution agreement signed with VWR to distribute Biocept's patented blood collection tube-- Co-Marketing agreement signed with Miraca Life Sciences-- Pathology Program initiative underway to expand adoption of Biocept's Target Selector™ platform to more community pathologists, oncologists and hematologists-- Newly launched liquid biopsy tests complete the complement of biomarker testing for breast cancer, metastatic melanoma and colorectal cancer under NCCN® Guidelines and bring the total number of commercially available liquid biopsy tests to 15-- Company to host conference call at 4:30 p.m. Eastern time today
View HTML
Toggle Summary Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017
SAN DIEGO , Nov. 2, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable  information to physicians to improve cancer treatment, announces that it will release financial
View HTML
Toggle Summary Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals
First and only platform that enables local pathologists to obtain molecular biomarker information from a simple blood sample using cutting-edge circulating tumor cell (CTC) technology
View HTML
Toggle Summary Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board
Expands Company's advisory board of oncology and academic leaders to eight members
View HTML
Toggle Summary Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States
MLS to market Biocept's proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future
View HTML
Toggle Summary Biocept Launches Liquid Biopsy Test for NRAS Mutations
Expands commercial offering to 15 clinically actionable biomarker tests, including key validated alterations listed in the NCCN Guidelines® for metastatic melanoma and colorectal cancer
View HTML
Toggle Summary Biocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco
SAN DIEGO , Aug. 28, 2017 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements
Leading clinical investigator to utilize Biocept's liquid biopsy tests for the detection of ALK rearrangements at baseline and to monitor treatment response and resistance mechanisms over time
View HTML